DelveInsight’s, “Nonalcoholic Steatohepatitis- Pipeline Insight, 2023” report provides comprehensive insights about 100+ companies and 150+ pipeline drugs in the Nonalcoholic Steatohepatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Got queries? Click here to know more about the Non-Alcoholic Steatohepatitis (NASH) Market Landscape.
Non-Alcoholic Steatohepatitis Overview
Nonalcoholic steatohepatitis is liver inflammation and damage caused by a fat buildup in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease can be divided into the isolated fatty liver in which there is only accumulation of fat, and nonalcoholic steatohepatitis (NASH), in which there is fat, inflammation, and damage to liver cells. In NASH, there is an abnormal amount of fat in the liver cells, but, in addition, in NASH, there is inflammation within the liver, and, as a result, the liver cells are damaged, they die, and are replaced by scar tissue. NASH progresses to scarring and ultimately to cirrhosis, with all the complications of cirrhosis, for example, gastrointestinal bleeding, liver failure, and liver cancer.
Non-Alcoholic Steatohepatitis Epidemiological Segmentation
Key companies in the Non-Alcoholic Steatohepatitis Market include:
And many others
Non-Alcoholic Steatohepatitis Therapies Covered in the report include
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
